Cost-effective reimbursement analysis for medical technologies in Europe
Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 15 EU countries
White Paper: Evidence Requirements for the Creation of IVD Reimbursement (NABM) Codes in France
Get insights from MTRC White Papers to advance your understanding on HAS assessments and evidence generation strategy for IVD tests in France
Recent news and posts
New version of the NABM nomenclature released in France
The Nomenclature of Medical Biology Procedures (NABM) serves as the primary and permanent reimbursement catalog for in-vitro diagnostic tests covered under statutory health insurance in France.
On January 13, 2026, a new version of the Nomenclature (NABM 101), effective from January 23, 2026, was released.
The updates include the creation of a new Chapter 21 "Constitutional genetics" with two new codes.
One of the newly introduced codes is 1004 "Postnatal DNA microarray hybridization" (coefficient B-1900). To obtain the tariff, the coefficient (i.e., 1900) should be multiplied by the B value, which is €0.25 for metropolitan France.
See the details in French here (NABM) and here (Order on NABM v.101 changes)
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.